This brand name is authorized in United States. It is also authorized in Japan.
The drug REVCOVI contains one active pharmaceutical ingredient (API):
1
|
UNII
9R3D3Y0UHS - ELAPEGADEMASE
|
|
Elapegademase is a recombinant adenosine deaminase (rADA). It provides an exogenous source of ADA enzyme that is associated with a decrease in toxic adenosine and deoxyadenosine nucleotides levels as well as an increase in lymphocyte number. Severe combined immune deficiency (SCID) associated with a deficiency of ADA enzyme is a rare, inherited, and often fatal disease. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| REVCOVI Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| JP | 医薬品医療機器総合機構 | 3959421A1023 |
| US | FDA, National Drug Code | 57665-002 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.